OVID: Advancing novel epilepsy and CNS therapies with strong clinical progress and major market potential
Novel therapies targeting neural hyperexcitability are advancing, with OV329 showing strong safety and efficacy in epilepsy and a billion-dollar market potential. The KCC2 portfolio, including a first-in-class oral activator, is progressing toward key milestones in schizophrenia and other CNS disor…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.